Health Care [ 6/12 ] | Biotechnology [ 40/75 ]
NASDAQ | Common Stock
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States.
The company develops therapies through its proprietary biologic drug platform technology (ETB).
It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors.
The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets.
Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 24 | -1.23 Increased by +56.84% | -1.44 Increased by +14.58% |
| May 15, 24 | 0.08 Decreased by -57.89% | -0.78 Increased by +110.26% |
| Mar 29, 24 | -0.73 Decreased by -87.18% | -0.97 Increased by +24.74% |
| Nov 13, 23 | -0.82 Decreased by -86.36% | -1.39 Increased by +41.01% |
| Aug 10, 23 | -2.85 Decreased by -547.73% | -5.17 Increased by +44.87% |
| May 15, 23 | 0.19 Increased by +150.00% | -0.28 Increased by +167.86% |
| Mar 30, 23 | -0.39 Decreased by -116.67% | -0.30 Decreased by -30.00% |
| Nov 10, 22 | -0.44 Increased by +18.52% | -0.48 Increased by +8.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 572.00 K Decreased by -91.37% | -8.10 M Increased by +25.50% | Decreased by -1.42 K% Decreased by -763.17% |
| Mar 31, 24 | 11.09 M Decreased by -67.03% | 572.00 K Decreased by -93.28% | Increased by +5.16% Decreased by -79.61% |
| Dec 31, 23 | 7.02 M Increased by +168.71% | -3.95 M Increased by +82.09% | Decreased by -56.27% Increased by +93.34% |
| Sep 30, 23 | 6.80 M Increased by +60.28% | 4.15 M Increased by +116.86% | Increased by +61.11% Increased by +110.52% |
| Jun 30, 23 | 6.63 M Increased by +50.03% | -10.87 M Increased by +57.63% | Decreased by -164.00% Increased by +71.76% |
| Mar 31, 23 | 33.63 M Increased by +296.26% | 8.51 M Increased by +137.67% | Increased by +25.31% Increased by +109.51% |
| Dec 31, 22 | 2.61 M Decreased by -85.47% | -22.05 M Decreased by -115.26% | Decreased by -844.47% Decreased by -1.38 K% |
| Sep 30, 22 | 4.24 M Increased by +78.23% | -24.64 M Increased by +18.92% | Decreased by -581.08% Increased by +54.51% |